DelveInsight has launched a new report on “Duchenne Muscular Dystrophy (DMD) – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Duchenne Muscular Dystrophy (DMD) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Duchenne Muscular Dystrophy (DMD), historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy (DMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
-
The total prevalent population of DMD in seven major markets was found to be 31,386 in 2017.
-
The total diagnosed prevalent cases of DMD patients were found to be maximum in the age- group 8-13 year and 14-19 year in the United States during the study period i.e. 2017-2030
-
A multinational study stated that the percentage was lowest at 16.6% in those in the early ambulatory stage (median age 7.2 years) and highest at 77.6% in the late non-ambulatory stage.
Key benefits of the report:
1. Duchenne Muscular Dystrophy (DMD) market report covers a descriptive overview and comprehensive insight of the Duchenne Muscular Dystrophy (DMD) epidemiology and Duchenne Muscular Dystrophy (DMD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Duchenne Muscular Dystrophy (DMD) market report provides insights on the current and emerging therapies.
3. Duchenne Muscular Dystrophy (DMD) market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Duchenne Muscular Dystrophy (DMD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Duchenne Muscular Dystrophy (DMD) market.
Request for sample pages: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
Duchenne Muscular Dystrophy (DMD): Overview
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. DMD is one of four conditions known as dystrophinopathies. The other three diseases that belong tothis group are Becker Muscular dystrophy (BMD, a mild form of DMD); an intermediate clinical presentation between DMD and BMD; and DMD-associated dilated cardiomyopathy (heart-disease) with little or no clinical skeletal, or voluntary, muscle disease.
The key players involved in Duchenne Muscular Dystrophy market:
-
Italfarmaco
-
Catabasis Pharmaceuticals
-
Santhera Pharmaceuticals
-
Hoffmann-La Roche
-
FibroGen
-
Capricor
-
Antisense Therapeutics
-
ReveraGen BioPharma
The launch of the emerging therapies is expected to significantly impact the Duchenne Muscular Dystrophy (DMD) treatment scenario in the upcoming years:-
Drug covered
-
Givinostat
-
Edasalonexent
-
Idebenone
-
RG6206 (BMS-986089)
-
Pamrevlumab
-
CAP-1002
-
ATL1102
-
Vamorolone
Request a free sample report @https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Duchenne Muscular Dystrophy (DMD) Patient Share (%) Overview at a Glance
5. Duchenne Muscular Dystrophy (DMD) Market Overview at a Glance
6. Duchenne Muscular Dystrophy (DMD) Disease Background and Overview
7. Duchenne Muscular Dystrophy (DMD) Epidemiology and Patient Population
8. Country-Specific Patient Population of Duchenne Muscular Dystrophy (DMD)
9. Duchenne Muscular Dystrophy (DMD) Current Treatment and Medical Practices
10. Unmet Needs
11. Duchenne Muscular Dystrophy (DMD) Emerging Therapies
12. Duchenne Muscular Dystrophy (DMD) Market Outlook
13. Country-Wise Duchenne Muscular Dystrophy (DMD) Market Analysis (2017–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Duchenne Muscular Dystrophy (DMD) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Duchenne Muscular Dystrophy- Pipeline Insights, 2021
“Duchenne Muscular Dystrophy Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Duchenne Muscular Dystrophy market. A detailed picture of the Duchenne Muscular Dystrophy pipeline landscape is provided, which includes the disease overview and Duchenne Muscular Dystrophy treatment guidelines.
Duchenne Muscular Dystrophy (DMD)- Epidemiology Forecast to 2030
DelveInsight’s ‘Duchenne Muscular Dystrophy- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/